Literature DB >> 17986615

Interaction of endosialin/TEM1 with extracellular matrix proteins mediates cell adhesion and migration.

Brian Tomkowicz1, Katherine Rybinski, Brian Foley, Wolfgang Ebel, Brad Kline, Eric Routhier, Philip Sass, Nicholas C Nicolaides, Luigi Grasso, Yuhong Zhou.   

Abstract

Endosialin/TEM1 was originally discovered as a human embryonic fibroblast-specific antigen and was later found to be differentially expressed in tumor stroma and endothelium. Endosialin/TEM1 overexpression has been observed in many cancers of various tissue origin, including colon, breast, pancreatic, and lung. The knockout (KO) mouse model showed the absence of endosialin/TEM1 expression reduced growth, invasion, and metastasis of human tumor xenografts. In addition, lack of endosialin/TEM1 led to an increase in small immature blood vessels and decreased numbers of medium and large tumor vessels. This abnormal angiogenic response could be responsible for the reduced tumor growth and invasion observed in endosialin/TEM1 KO mice, suggesting a role for endosialin/TEM1 in controlling the interaction among tumor cells, endothelia, and stromal matrix. Here we report the identification of fibronectin (FN) and collagen types I and IV as specific ligands for endosialin/TEM1. More importantly, cells expressing endosialin/TEM1 exhibit enhanced adhesion to FN as well as enhanced migration through matrigel, although these properties could be blocked by a humanized antibody directed against human endosialin/TEM1. Our results pinpoint to a molecular mechanism by which expression of endosialin/TEM1 in the tumor stroma and endothelium may support tumor progression and invasion.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17986615      PMCID: PMC2084280          DOI: 10.1073/pnas.0705647104

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  26 in total

1.  Pathological angiogenesis is reduced by targeting pericytes via the NG2 proteoglycan.

Authors:  Ugur Ozerdem; William B Stallcup
Journal:  Angiogenesis       Date:  2004       Impact factor: 9.596

Review 2.  Endothelial/pericyte interactions.

Authors:  Annika Armulik; Alexandra Abramsson; Christer Betsholtz
Journal:  Circ Res       Date:  2005-09-16       Impact factor: 17.367

Review 3.  Pericyte physiology.

Authors:  D Shepro; N M Morel
Journal:  FASEB J       Date:  1993-08       Impact factor: 5.191

4.  Prognostic values of tumor endothelial markers in patients with colorectal cancer.

Authors:  K A Rmali; M C A Puntis; W G Jiang
Journal:  World J Gastroenterol       Date:  2005-03-07       Impact factor: 5.742

5.  Expression of stromal cell markers in distinct compartments of human skin cancers.

Authors:  Margit A Huber; Norbert Kraut; Norbert Schweifer; Helmut Dolznig; Ralf U Peter; Roland D Schubert; Karin Scharffetter-Kochanek; Hubert Pehamberger; Pilar Garin-Chesa
Journal:  J Cutan Pathol       Date:  2006-02       Impact factor: 1.587

Review 6.  Potential regulation of cartilage metabolism in osteoarthritis by fibronectin fragments.

Authors:  G A Homandberg
Journal:  Front Biosci       Date:  1999-10-15

7.  Human endosialin (tumor endothelial marker 1) is abundantly expressed in highly malignant and invasive brain tumors.

Authors:  Jennifer Brady; James Neal; Nagarajan Sadakar; Philippe Gasque
Journal:  J Neuropathol Exp Neurol       Date:  2004-12       Impact factor: 3.685

8.  Substratum-dependent stimulation of fibroblast migration by the gelatin-binding domain of fibronectin.

Authors:  S L Schor; I Ellis; C Dolman; J Banyard; M J Humphries; D F Mosher; A M Grey; A P Mould; J Sottile; A M Schor
Journal:  J Cell Sci       Date:  1996-10       Impact factor: 5.285

9.  Characterization of cancer stroma markers: in silico analysis of an mRNA expression database for fibroblast activation protein and endosialin.

Authors:  Helmut Dolznig; Norbert Schweifer; Christina Puri; Norbert Kraut; Wolfgang J Rettig; Dontscho Kerjaschki; Pilar Garin-Chesa
Journal:  Cancer Immun       Date:  2005-08-03

10.  Endosialin (TEM1, CD248) is a marker of stromal fibroblasts and is not selectively expressed on tumour endothelium.

Authors:  John R MacFadyen; Oliver Haworth; David Roberston; Deborah Hardie; Marie-Therese Webster; Howard R Morris; Maria Panico; Mark Sutton-Smith; Anne Dell; Peter van der Geer; Dirk Wienke; Christopher D Buckley; Clare M Isacke
Journal:  FEBS Lett       Date:  2005-04-07       Impact factor: 4.124

View more
  63 in total

1.  A first-in-human phase I study of MORAb-004, a monoclonal antibody to endosialin in patients with advanced solid tumors.

Authors:  Luis A Diaz; Christina M Coughlin; Susan C Weil; Jean Fishel; Mrinal M Gounder; Susan Lawrence; Nilofer Azad; Daniel J O'Shannessy; Luigi Grasso; Jason Wustner; Wolfgang Ebel; Richard D Carvajal
Journal:  Clin Cancer Res       Date:  2014-11-14       Impact factor: 12.531

Review 2.  Insidious changes in stromal matrix fuel cancer progression.

Authors:  Fayth L Miles; Robert A Sikes
Journal:  Mol Cancer Res       Date:  2014-01-22       Impact factor: 5.852

3.  Phase 1 trial of ontuxizumab (MORAb-004) in children with relapsed or refractory solid tumors: A report from the Children's Oncology Group Phase 1 Pilot Consortium (ADVL1213).

Authors:  Robin E Norris; Elizabeth Fox; Joel M Reid; Andrew Ralya; Xiaowei W Liu; Charles Minard; Brenda J Weigel
Journal:  Pediatr Blood Cancer       Date:  2018-01-02       Impact factor: 3.167

Review 4.  C-type lectin family XIV members and angiogenesis.

Authors:  Supriya Borah; Dileep Vasudevan; Rajeeb K Swain
Journal:  Oncol Lett       Date:  2019-08-16       Impact factor: 2.967

5.  Rapid isolation of high-affinity human antibodies against the tumor vascular marker Endosialin/TEM1, using a paired yeast-display/secretory scFv library platform.

Authors:  Aizhi Zhao; Selene Nunez-Cruz; Chunsheng Li; George Coukos; Don L Siegel; Nathalie Scholler
Journal:  J Immunol Methods       Date:  2010-09-15       Impact factor: 2.303

6.  Characterization and angiogenic potential of human neonatal and infant thymus mesenchymal stromal cells.

Authors:  Shuyun Wang; Lakshmi Mundada; Sean Johnson; Joshua Wong; Russell Witt; Richard G Ohye; Ming-Sing Si
Journal:  Stem Cells Transl Med       Date:  2015-02-23       Impact factor: 6.940

7.  Development of 124I immuno-PET targeting tumor vascular TEM1/endosialin.

Authors:  Ann-Marie Chacko; Chunsheng Li; Madhura Nayak; John L Mikitsh; Jia Hu; Catherine Hou; Luigi Grasso; Nicholas C Nicolaides; Vladimir R Muzykantov; Chaitanya R Divgi; George Coukos
Journal:  J Nucl Med       Date:  2014-02-13       Impact factor: 10.057

8.  Antibody-based tumor vascular theranostics targeting endosialin/TEM1 in a new mouse tumor vascular model.

Authors:  Chunsheng Li; Ann-Marie Chacko; Jia Hu; Kosei Hasegawa; Jennifer Swails; Luigi Grasso; Wafik S El-Deiry; Nicholas Nicolaides; Vladimir R Muzykantov; Chaitanya R Divgi; George Coukos
Journal:  Cancer Biol Ther       Date:  2014-02-19       Impact factor: 4.742

9.  Tumor endothelial marker 1-specific DNA vaccination targets tumor vasculature.

Authors:  John G Facciponte; Stefano Ugel; Francesco De Sanctis; Chunsheng Li; Liping Wang; Gautham Nair; Sandy Sehgal; Arjun Raj; Efthymia Matthaiou; George Coukos; Andrea Facciabene
Journal:  J Clin Invest       Date:  2014-03-18       Impact factor: 14.808

10.  Characterization of TEM1/endosialin in human and murine brain tumors.

Authors:  Eleanor B Carson-Walter; Bethany N Winans; Melissa C Whiteman; Yang Liu; Sally Jarvela; Hannu Haapasalo; Betty M Tyler; David L Huso; Mahlon D Johnson; Kevin A Walter
Journal:  BMC Cancer       Date:  2009-11-30       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.